@TheCancerLetter
cancerletter.com FDA grants priority review to Brukinsa combination for first-line mantle cell lymphoma - The Cancer... FDA accepted and granted Priority Review to the supplemental New Drug Application for Brukinsa (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously... 
cancerletter.com Federal judge rejects CMS definition of “medically frail” to earn Medicaid work requirement... A federal judge ruled that states will not need to require evidence from “medically frail” beneficiaries, proving their illness precludes them from work, in order to qualify for an exemption to the... 
cancerletter.com FDA approves Rybrevant Faspro as dual-targeted therapy for advanced head and neck cancer - The... FDA granted accelerated approval for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) (subcutaneous injection, 160 mg/2,000 units per mL) as a single agent for the treatment of adults with... 
cancerletter.com Democrats vow to undo Trump’s Medicaid cuts, reverse ACA dismantling - The Cancer Letter In a victory speech on Nov. 4, Rep. Hakeem Jeffries (D-NY), the presumed next speaker of the House, ran through the bread-and-butter concerns which gave Democrats House and Senate majorities not seen... 
cancerletter.com Community sites have the patients to boost trial enrollment—but not the infrastructure - The Cancer... I have spent over 20 years running a tumor imaging metrics core at an academic cancer center. In that time, I have watched clinical trial enrollment concentrate at a relatively small number of... 